Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

A two-stage patient enrichment adaptive design in phase II oncology trials.

Song JX.

Contemp Clin Trials. 2014 Jan;37(1):148-54. doi: 10.1016/j.cct.2013.12.001.

PMID:
24342820
2.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials..

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Review.

PMID:
18477802
3.

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ.

Clin Trials. 2008;5(3):181-93. doi: 10.1177/1740774508091815.

PMID:
18559407
4.

A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.

Xie F, Ji Y, Tremmel L.

Contemp Clin Trials. 2012 Jul;33(4):739-48. doi: 10.1016/j.cct.2012.03.001.

PMID:
22426247
5.

The use of phase 2 interim analysis to expedite drug development decisions.

Huang J, Das A, Burger HU, Zhong W, Zhang W, Lieberman G.

Contemp Clin Trials. 2014 Jul;38(2):235-44. doi: 10.1016/j.cct.2014.05.006.

PMID:
24854415
6.

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.

Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL.

Cancer. 2010 Oct 1;116(19):4590-6. doi: 10.1002/cncr.25257.

7.
8.

Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach.

Chen Y, Smith BJ.

Stat Med. 2009 Nov 30;28(27):3347-62. doi: 10.1002/sim.3711.

PMID:
19725024
9.

The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.

Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG.

J Biopharm Stat. 2015;25(1):66-88. doi: 10.1080/10543406.2014.919933.

10.

A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.

Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, Kudo M, Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y.

Eur J Cancer. 2013 Sep;49(13):2832-40. doi: 10.1016/j.ejca.2013.05.011.

PMID:
23764238
11.

[Hepatocellular carcinoma].

Kondo S, Ueno H, Morizane C, Okusaka T.

Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23. Japanese.

PMID:
20647702
12.

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.

Renfro LA, Coughlin CM, Grothey AM, Sargent DJ.

Chin Clin Oncol. 2014 Mar;3(1):3. doi: 10.3978/j.issn.2304-3865.2013.12.04.

13.

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.

Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX.

Oncologist. 2009 Jul;14(7):717-25. doi: 10.1634/theoncologist.2009-0038.

14.

An adaptive design for phase II non-oncology dose selection clinical trials.

Su Z.

Clin Drug Investig. 2010;30(6):397-403. doi: 10.2165/11533340-000000000-00000.

PMID:
20373828
15.

High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.

Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, Chen W, Hu S.

J Gastrointest Surg. 2012 Apr;16(4):828-36. doi: 10.1007/s11605-011-1775-4.

PMID:
22072303
16.

The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.

Chen D, Xing W, Hong J, Wang M, Huang Y, Zhu C, Yuan Y, Zeng W.

Ann Surg Oncol. 2012 Oct;19(11):3556-65. doi: 10.1245/s10434-012-2396-1.

PMID:
22588469
17.

Time-to-event analysis with treatment arm selection at interim.

Di Scala L, Glimm E.

Stat Med. 2011 Nov 20;30(26):3067-81. doi: 10.1002/sim.4342. Erratum in: Stat Med. 2013 May 20;32(11):1974.

PMID:
21898523
18.

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.

J Hepatol. 2012 Jul;57(1):101-7. doi: 10.1016/j.jhep.2012.02.016.

PMID:
22414760
19.

Resampling phase III data to assess phase II trial designs and endpoints.

Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ.

Clin Cancer Res. 2012 Apr 15;18(8):2309-15. doi: 10.1158/1078-0432.CCR-11-1815.

Supplemental Content

Support Center